Trial Profile
A Randomized, Double Blind Study to Assess the Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 23 Jul 2010 New trial record